Strategic Partnerships Opportunity to leverage existing and past collaborations with big pharma players (GlaxoSmithKline, Alexion) and BridgeBio affinity to pursue co development or regional licensing deals, especially in Japan and ATTR market segments.

Acquisition & Integration BridgeBio acquisition of Eidos suggests strong upside for distribution, commercialization support, and integration of AG10 programs; explore opportunities to align sales enablement, contract manufacturing, or clinical supply partnerships with BridgeBio ecosystem.

Specialty Market Focus Target ATTR cardiomyopathy and polyneuropathy clinicians, transplant and cardiology centers, and patient advocacy channels; potential to partner with specialty distributors and KOL networks to accelerate adoption of AG10 once available.

Early Stage Signals Eidos operates with mid-size headcount and a modest revenue base; identify opportunities in contract research, clinical supply chain services, or CRO/CSO collaborations to support ongoing or upcoming trials and maintain agile operations.

Data & Digital Readiness Current tech stack indicates readiness for CRM, analytics, digital marketing, and eSignature adoption; propose value-added solutions for regulated e-clinical, data management, and payer engagement to streamline market access.